Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

Abstract

The addition of cobimetinib to vemurafenib was associated with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity. (Funded by F. Hoffmann-La Roche/Genentech; coBRIM ClinicalTrials.gov number, NCT01689519.).

Keywords

VemurafenibMedicineHazard ratioInternal medicineOncologyPlaceboInterim analysisMelanomaConfidence intervalProgression-free survivalClinical endpointV600ERandomized controlled trialGastroenterologyOverall survivalMetastatic melanomaCancer researchCancerPathologyMutationBiology

Affiliated Institutions

Related Publications

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Publication Info

Year: 2014
Type: article
Volume: 371
Issue: 20
Pages: 1867-1876
Citations: 1969
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1969

OpenAlex

Cite This

APA Style

                            
                                
                                    James Larkin, 
                                
                                    Paolo A. Ascierto, 
                                
                                    Brigitte Dréno
                                
                                et al.
                            
                            (2014). 
                            Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. 
                            New England Journal of Medicine
                            , 371
                            (20)
                            , 1867-1876.
                            https://doi.org/10.1056/nejmoa1408868
                        

Identifiers

DOI: 10.1056/nejmoa1408868